205 related articles for article (PubMed ID: 16417253)
1. Improved biodistribution and radioimmunoimaging with poly(ethylene glycol)-DOTA-conjugated anti-CEA diabody.
Li L; Yazaki PJ; Anderson AL; Crow D; Colcher D; Wu AM; Williams LE; Wong JY; Raubitschek A; Shively JE
Bioconjug Chem; 2006; 17(1):68-76. PubMed ID: 16417253
[TBL] [Abstract][Full Text] [Related]
2. Tumor targeting of radiometal labeled anti-CEA recombinant T84.66 diabody and t84.66 minibody: comparison to radioiodinated fragments.
Yazaki PJ; Wu AM; Tsai SW; Williams LE; Ikler DN; Wong JY; Shively JE; Raubitschek AA
Bioconjug Chem; 2001; 12(2):220-8. PubMed ID: 11312683
[TBL] [Abstract][Full Text] [Related]
3. Site-specific conjugation of monodispersed DOTA-PEGn to a thiolated diabody reveals the effect of increasing peg size on kidney clearance and tumor uptake with improved 64-copper PET imaging.
Li L; Crow D; Turatti F; Bading JR; Anderson AL; Poku E; Yazaki PJ; Carmichael J; Leong D; Wheatcroft D; Raubitschek AA; Hudson PJ; Colcher D; Shively JE
Bioconjug Chem; 2011 Apr; 22(4):709-16. PubMed ID: 21395337
[TBL] [Abstract][Full Text] [Related]
4. Monodispersed DOTA-PEG-conjugated anti-TAG-72 diabody has low kidney uptake and high tumor-to-blood ratios resulting in improved 64Cu PET.
Li L; Turatti F; Crow D; Bading JR; Anderson AL; Poku E; Yazaki PJ; Williams LE; Tamvakis D; Sanders P; Leong D; Raubitschek A; Hudson PJ; Colcher D; Shively JE
J Nucl Med; 2010 Jul; 51(7):1139-46. PubMed ID: 20554731
[TBL] [Abstract][Full Text] [Related]
5. Reduction of kidney uptake in radiometal labeled peptide linkers conjugated to recombinant antibody fragments. Site-specific conjugation of DOTA-peptides to a Cys-diabody.
Li L; Olafsen T; Anderson AL; Wu A; Raubitschek AA; Shively JE
Bioconjug Chem; 2002; 13(5):985-95. PubMed ID: 12236780
[TBL] [Abstract][Full Text] [Related]
6. Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging.
Olafsen T; Kenanova VE; Sundaresan G; Anderson AL; Crow D; Yazaki PJ; Li L; Press MF; Gambhir SS; Williams LE; Wong JY; Raubitschek AA; Shively JE; Wu AM
Cancer Res; 2005 Jul; 65(13):5907-16. PubMed ID: 15994969
[TBL] [Abstract][Full Text] [Related]
7. 124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice.
Sundaresan G; Yazaki PJ; Shively JE; Finn RD; Larson SM; Raubitschek AA; Williams LE; Chatziioannou AF; Gambhir SS; Wu AM
J Nucl Med; 2003 Dec; 44(12):1962-9. PubMed ID: 14660722
[TBL] [Abstract][Full Text] [Related]
8. Metabolism and renal clearance of 111In-labeled DOTA-conjugated antibody fragments.
Tsai SW; Li L; Williams LE; Anderson AL; Raubitschek AA; Shively JE
Bioconjug Chem; 2001; 12(2):264-70. PubMed ID: 11312688
[TBL] [Abstract][Full Text] [Related]
9. Tumor uptake of pegylated diabodies: Balancing systemic clearance and vascular transport.
Li Q; White JB; Peterson NC; Rickert KW; Lloyd CO; Allen KL; Rosenthal K; Gao X; Wu H; Dall'Acqua WF; Borrok MJ; Tsui P
J Control Release; 2018 Jun; 279():126-135. PubMed ID: 29653224
[TBL] [Abstract][Full Text] [Related]
10. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.
Chen X; Hou Y; Tohme M; Park R; Khankaldyyan V; Gonzales-Gomez I; Bading JR; Laug WE; Conti PS
J Nucl Med; 2004 Oct; 45(10):1776-83. PubMed ID: 15471848
[TBL] [Abstract][Full Text] [Related]
11. Effects of linker variation on the in vitro and in vivo characteristics of an 111In-labeled RGD peptide.
Dijkgraaf I; Liu S; Kruijtzer JA; Soede AC; Oyen WJ; Liskamp RM; Corstens FH; Boerman OC
Nucl Med Biol; 2007 Jan; 34(1):29-35. PubMed ID: 17210459
[TBL] [Abstract][Full Text] [Related]
12. Biodistribution of 111In- and 90Y-labeled DOTA and maleimidocysteineamido-DOTA conjugated to chimeric anticarcinoembryonic antigen antibody in xenograft-bearing nude mice: comparison of stable and chemically labile linker systems.
Williams LE; Lewis MR; Bebb GG; Clarke KG; Odom-Maryon TL; Shively JE; Raubitschek AA
Bioconjug Chem; 1998; 9(1):87-93. PubMed ID: 9460550
[TBL] [Abstract][Full Text] [Related]
13. Radioiodinated versus radiometal-labeled anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments: optimal pharmacokinetics for therapy.
Kenanova V; Olafsen T; Williams LE; Ruel NH; Longmate J; Yazaki PJ; Shively JE; Colcher D; Raubitschek AA; Wu AM
Cancer Res; 2007 Jan; 67(2):718-26. PubMed ID: 17234783
[TBL] [Abstract][Full Text] [Related]
14. Numerical selection of optimal tumor imaging agents with application to engineered antibodies.
Williams LE; Wu AM; Yazaki PJ; Liu A; Raubitschek AA; Shively JE; Wong JY
Cancer Biother Radiopharm; 2001 Feb; 16(1):25-35. PubMed ID: 11279795
[TBL] [Abstract][Full Text] [Related]
15. In vivo biodistribution, PET imaging, and tumor accumulation of 86Y- and 111In-antimindin/RG-1, engineered antibody fragments in LNCaP tumor-bearing nude mice.
Schneider DW; Heitner T; Alicke B; Light DR; McLean K; Satozawa N; Parry G; Yoo J; Lewis JS; Parry R
J Nucl Med; 2009 Mar; 50(3):435-43. PubMed ID: 19223400
[TBL] [Abstract][Full Text] [Related]
16. PET imaging of colorectal cancer in xenograft-bearing mice by use of an 18F-labeled T84.66 anti-carcinoembryonic antigen diabody.
Cai W; Olafsen T; Zhang X; Cao Q; Gambhir SS; Williams LE; Wu AM; Chen X
J Nucl Med; 2007 Feb; 48(2):304-10. PubMed ID: 17268029
[TBL] [Abstract][Full Text] [Related]
17. A multivalent recombinant antibody fragment specific for carcinoembryonic antigen.
Perez L; Ayala M; Pimentel G; Bell H; Canaán-Haden L; Bequet M; González LJ; Miranda M; Ravelo R; Roque L; Acevedo B; Oliva JP; Gavilondo JV
Biotechnol Appl Biochem; 2006 Jan; 43(Pt 1):39-48. PubMed ID: 16101587
[TBL] [Abstract][Full Text] [Related]
18. Panitumumab Modified with Metal-Chelating Polymers (MCP) Complexed to
Aghevlian S; Lu Y; Winnik MA; Hedley DW; Reilly RM
Mol Pharm; 2018 Mar; 15(3):1150-1159. PubMed ID: 29314858
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
